Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026)
Sol-Gel Technologies (SLGL) reported Income from Continuing Operations of 3855000.0 for Q1 2026, down 57.49% year-over-year from 9069000.0 in Q1 2025, and up 213.02% quarter-over-quarter from 3411000.0 in Q4 2025.
Sol-Gel Technologies (SLGL) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has 10 years of Income from Continuing Operations data on file, last reported at 3855000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 3855000.0, down 57.49% year-over-year; the trailing twelve-month figure through Mar 2026 was 5386000.0 (up 43.02% YoY), and the FY2025 annual result was 7538000.0, up 37.26% from the prior year.
- Income from Continuing Operations improved to 3855000.0 in Q1 2026 per SLGL's latest filing, from 3411000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 11230000.0 in Q2 2025 and troughed at 6527000.0 in Q2 2023.
- A 5-year average of 309941.18 and a median of 828000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations plunged 1509.72% in 2023, then surged 591.5% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 6205000.0 in 2022, then advanced by 12.86% to 5407000.0 in 2023, then dropped by 12.8% to 6099000.0 in 2024, then surged by 44.07% to 3411000.0 in 2025, then soared by 213.02% to 3855000.0 in 2026.
- Business Quant data shows SLGL's Income from Continuing Operations at 3855000.0 in Q1 2026, 3411000.0 in Q4 2025, and 6288000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Sol-Gel Technologies | 207.80 Mn | 197.67 Mn | - | 3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | -3.41 Mn |
| Sep 30, 2025 | -6.29 Mn |
| Jun 30, 2025 | 11.23 Mn |
| Mar 31, 2025 | 9.07 Mn |
| Dec 31, 2024 | -6.10 Mn |
| Sep 30, 2024 | -828,000.00 |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 6.71 Mn |
| Dec 31, 2023 | -5.41 Mn |
| Sep 30, 2023 | -6.31 Mn |
| Jun 30, 2023 | -6.53 Mn |
| Mar 31, 2023 | 11.06 Mn |
| Dec 31, 2022 | -6.21 Mn |
| Sep 30, 2022 | -3.63 Mn |
| Jun 30, 2022 | 463,000.00 |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 13.96 Mn |
| Sep 30, 2021 | 1.27 Mn |
| Jun 30, 2021 | 8.04 Mn |